CanSino Biologics Management
Management criteria checks 2/4
CanSino Biologics' CEO is Xuefeng Yu, appointed in Jan 2009, has a tenure of 15.33 years. directly owns 7.24% of the company’s shares, worth HK$628.76M. The average tenure of the management team and the board of directors is 6.3 years and 4.5 years respectively.
Key information
Xuefeng Yu
Chief executive officer
CN¥4.9m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 15.3yrs |
| CEO ownership | 7.2% |
| Management average tenure | 6.3yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically
Apr 07
Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?
Feb 06CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
Oct 13Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be
Sep 07CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
May 12Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
Jan 09CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up
Sep 16Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade
Aug 31Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?
Aug 29Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts
Jul 13Is CanSino Biologics (HKG:6185) Using Too Much Debt?
Jul 01We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt
Mar 15CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%
Jan 11Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?
Dec 26CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly
Oct 01CanSino Biologics' (HKG:6185) Earnings Aren't As Good As They Appear
Sep 05Is CanSino Biologics (HKG:6185) Using Debt In A Risky Way?
Jul 03CEO
Xuefeng Yu (58 yo)
15.3yrs
Tenure
CN¥4,940,000
Compensation
Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.3yrs | CN¥4.94m | 7.24% CN¥ 628.8m | |
| Co-Founder | 15.3yrs | CN¥4.98m | 7.24% CN¥ 628.8m | |
| Co-Founder | 15.3yrs | CN¥4.61m | 6.93% CN¥ 602.0m | |
| COO, Deputy GM & Executive Director | 6yrs | CN¥4.91m | no data | |
| Chief Commercial Officer | 2.7yrs | CN¥3.97m | no data | |
| Senior Director of New Technology Department | 6.5yrs | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Board Secretary | 5.2yrs | no data | no data | |
| Joint Company Secretary | 5.2yrs | no data | no data |
6.3yrs
Average Tenure
49yo
Average Age
Experienced Management: 6185's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.3yrs | CN¥4.94m | 7.24% CN¥ 628.8m | |
| Co-Founder | 15.3yrs | CN¥4.98m | 7.24% CN¥ 628.8m | |
| Co-Founder | 15.3yrs | CN¥4.61m | 6.93% CN¥ 602.0m | |
| COO, Deputy GM & Executive Director | 5.9yrs | CN¥4.91m | no data | |
| Chief Commercial Officer | 2.6yrs | CN¥3.97m | no data | |
| Co-Chair of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Independent Non-Executive Director | 4.5yrs | CN¥300.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Employee Representative Supervisor | less than a year | no data | no data | |
| Independent Non-Executive Director | 4.5yrs | CN¥300.00k | 0.00040% CN¥ 34.8k | |
| Co-Chair of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Independent Non-Executive Director | no data | no data | no data |
4.5yrs
Average Tenure
58yo
Average Age
Experienced Board: 6185's board of directors are considered experienced (4.5 years average tenure).